|Bid||108.07 x 800|
|Ask||108.64 x 800|
|Day's Range||107.90 - 108.94|
|52 Week Range||104.17 - 132.13|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||13.71|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||2.58 (2.39%)|
|1y Target Est||125.33|
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Bank of America Merrill Lynch’s Geoff Meacham sees the clouds lifting for the sector. He issued Buy ratings on four major names in the sector.
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S. stock futures were weaker Wednesday morning, and bond yields fell on concerns over U.S.-China tensions and no fresh progress on Brexit talks.
Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study. The trial evaluated Lilly's pegilodecakin plus Folfox, which is a combination of chemotherapy drugs, compared to Folfox alone in patients with metastatic pancreatic cancer. Lilly gained access to pegilodecakin with its $1.6 billion acquisition of Armo Biosciences.
Eli Lilly and Co. said Wednesday a late-stage trail of a treatment for pancreatic cancer did not meet its main goal of overall survival. The company said detailed results of the phase 3 trial called Sequoia evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer will be presented at a future medical meeting. Metastatic pancreatic cancer is one of the deadliest major cancers with just 3% of patients that are diagnosed in the U.S. surviving five years after being diagnosed. The disease is the third leading cause of cancer deaths and is expected to become the second leading cause in the next 10 years. "While we are disappointed by the outcome of the SEQUOIA study, we look forward to the upcoming results in lung cancer, learning from those results and increasing our understanding of pegilodecakin's novel mechanism of action in cancer immunotherapy," Maura Dickler, vice president of late phase development at Lilly Oncology said in a statement. Eli Lilly shares were not yet active premarket, but have fallen 5% in 2019, while the S&P 500 has gained 19.5%.
INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen. The SEQUOIA trial did not meet its primary endpoint of overall survival. The most common Grade 3/4 adverse events occurring at a higher rate ( 5% difference) on the pegilodecakin-plus-FOLFOX arm compared to the FOLFOX arm were neutropenia, thrombocytopenia, fatigue and anemia.
With year-end rapidly approaching, now is the time to take steps to cut your 2019 tax bill before it’s too late. If your total itemizable deductions for 2019 will be close to your standard deduction amount, consider making enough additional expenditures for itemized deduction items before year-end to exceed the standard deduction. Next year, your standard deduction will be a bit bigger thanks to an inflation adjustment, and you can claim it then.
The late-stage trial of patients with metastatic pancreatic cancer 'did not meet its primary endpoint of overall survival,' Eli Lilly says.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...
INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists). "Millions of people with migraine face an ongoing battle with the unresolved pain and symptoms of a migraine attack.
The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow. The drug has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults. Lilly acquired Reyvow, formerly called lasmiditan, in a deal https://www.reuters.com/article/us-colucid-pharms-m-a-eli-lilly-idUSKBN1521O6 worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early 2017.
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
Rising health costs have become a burden for many Americans, but many people still may be unaware of one benefit they get, the health savings account. Personal finance expert Jean Chatzky joins Yahoo Finance to discuss the benefits of HSAs.